659 related articles for article (PubMed ID: 9273082)
1. [Diagnosis of cancer of the prostate (I): Advancements in knowledge and practice since the consensus conference of 1989. The "Cancer of the Prostate" subcommittee of the Committee of Oncology of the French Association of Urology].
Villers A; Grosclaude P; Haillot O; Abbou CC; Richard F; Boccon-Gibod L
Prog Urol; 1997 Jun; 7(3):508-15. PubMed ID: 9273082
[TBL] [Abstract][Full Text] [Related]
2. [Prostate cancer screening].
Villers A; Rébillard X; Soulié M; Davin JL; Coloby P; Moreau JL; Mejean A; Irani J; Coulange C; Mangin P;
Prog Urol; 2003 Apr; 13(2):209-14. PubMed ID: 12765053
[TBL] [Abstract][Full Text] [Related]
3. [Prostate cancer screening (III): risk factors, natural history, course without treatment. Characteristics of detected cancers].
Villers A; Soulié M; Haillot O; Boccon-Gibod L
Prog Urol; 1997 Sep; 7(4):655-61. PubMed ID: 9410329
[TBL] [Abstract][Full Text] [Related]
4. [Advancements in PSA-based screening for prostate cancer].
Ito K
Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
[TBL] [Abstract][Full Text] [Related]
5. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
6. [Screening of cancer of the prostate (IV). Economic approach: the costs of screening tests and treatment. Members of the Sub-Committee of the Prostate of CCAFU].
Haillot O; Villers A; Soulie M; Baron JC
Prog Urol; 1998 Sep; 8(4):517-23. PubMed ID: 9834514
[TBL] [Abstract][Full Text] [Related]
7. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
8. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
Bourel M; Ardaillou R;
Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
[TBL] [Abstract][Full Text] [Related]
9. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
Krahn MD; Coombs A; Levy IG
CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
[TBL] [Abstract][Full Text] [Related]
10. The case for prostate cancer screening.
Andriole GL
Semin Urol; 1993 May; 11(2):50-3. PubMed ID: 7689738
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.
Hernández J; Thompson IM
Cancer; 2004 Sep; 101(5):894-904. PubMed ID: 15329895
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis, management and screening of early localised prostate cancer.
Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
[TBL] [Abstract][Full Text] [Related]
14. [PSA related screening of prostate cancer. Panic or improvement?].
Fornara P; Jurczok A
Aktuelle Urol; 2004 Feb; 35(1):43-8. PubMed ID: 14997414
[TBL] [Abstract][Full Text] [Related]
15. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
[TBL] [Abstract][Full Text] [Related]
16. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
Lim LS; Sherin K;
Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
[TBL] [Abstract][Full Text] [Related]
17. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
[TBL] [Abstract][Full Text] [Related]
18. Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?
Albertsen PC
Acta Oncol; 2005; 44(3):255-64. PubMed ID: 16076698
[TBL] [Abstract][Full Text] [Related]
19. American Cancer Society guideline for the early detection of prostate cancer: update 2010.
Wolf AM; Wender RC; Etzioni RB; Thompson IM; D'Amico AV; Volk RJ; Brooks DD; Dash C; Guessous I; Andrews K; DeSantis C; Smith RA;
CA Cancer J Clin; 2010; 60(2):70-98. PubMed ID: 20200110
[TBL] [Abstract][Full Text] [Related]
20. The Japanese guideline for prostate cancer screening.
Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T
Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
